What is the address of LB Clinical Biology?

The registered office of LB Clinical Biology is located at Rue du Sart-Mathelet 2 box A, 5336 Assesse.

Is LB Clinical Biology still active?

Yes. According to the CBE (31 October 2026) LB Clinical Biology is active, legal situation “Normale toestand”, started on 12 October 2021.

Is LB Clinical Biology registered on Peppol?

Yes, LB Clinical Biology is registered on the Peppol network with ID 0208:0775653669.

What is the enterprise number of LB Clinical Biology?

The enterprise number of LB Clinical Biology is BE0775653669.

When was LB Clinical Biology founded?

LB Clinical Biology was founded on 12 October 2021.

Who are the directors of LB Clinical Biology?

According to the 2025 annual accounts, the directors of LB Clinical Biology are: Benjamin Lardinois.

Is LB Clinical Biology a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 October 2021; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did LB Clinical Biology make in 2025?

LB Clinical Biology posted a profit after taxes of € 192,145 in financial year 2025.

What is the revenue of LB Clinical Biology?

As a small company, LB Clinical Biology is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 255,096.

LB Clinical Biology (Private Limited) - Assesse

Dossier LB Clinical Biology, printed on 31 October 2026 from databakkes.be/en/0775653669/lb-clinical-biology. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

LB Clinical Biology from Assesse, company number BE0775653669, closed financial year 2025 with a result of € 192,145 after tax. For that financial year LB Clinical Biology recorded a gross margin of € 255,096 and equity of € 404,993. Compared with financial year 2024, the result moved from € 118,802 to € 192,145. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 6, 2026.

What it is worth Growing

€ 404,993

▲ 34% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 192,145

▲ 62% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 217,274

▲ 125% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 90,000 paid out

47 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 563

▼ 82% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 1,719

▼ 70% vs 2024

Loans from banks and other lenders, long and short.

Taxes

€ 59,392

▲ 74% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 123,309 Gross margin 2022: € 123,309 First fiscal year in the series	€ 116,163 Gross margin 2023: € 116,163 ▼ 6% vs 2022 (€ 123,309) Unfavourable step	€ 158,303 Gross margin 2024: € 158,303 ▲ 36% vs 2023 (€ 116,163) Favourable step	€ 255,096 Gross margin 2025: € 255,096 ▲ 61% vs 2024 (€ 158,303) Favourable step	▲ 61%
Profit after taxes	€ 93,586 Profit after taxes 2022: € 93,586 First fiscal year in the series	€ 86,460 Profit after taxes 2023: € 86,460 ▼ 8% vs 2022 (€ 93,586) Unfavourable step	€ 118,802 Profit after taxes 2024: € 118,802 ▲ 37% vs 2023 (€ 86,460) Favourable step	€ 192,145 Profit after taxes 2025: € 192,145 ▲ 62% vs 2024 (€ 118,802) Favourable step	▲ 62%
Equity	€ 97,586 Equity 2022: € 97,586 First fiscal year in the series	€ 184,046 Equity 2023: € 184,046 ▲ 89% vs 2022 (€ 97,586) Favourable step	€ 302,848 Equity 2024: € 302,848 ▲ 65% vs 2023 (€ 184,046) Favourable step	€ 404,993 Equity 2025: € 404,993 ▲ 34% vs 2024 (€ 302,848) Favourable step	▲ 34%
Total debts	€ 39,386 Total debts 2022: € 39,386 First fiscal year in the series	€ 35,967 Total debts 2023: € 35,967 ▼ 9% vs 2022 (€ 39,386) Favourable step	€ 39,913 Total debts 2024: € 39,913 ▲ 11% vs 2023 (€ 35,967) Unfavourable step	€ 151,111 Total debts 2025: € 151,111 ▲ 279% vs 2024 (€ 39,913) Unfavourable step	▲ 279%
Cash	€ 65,145 Cash 2022: € 65,145 First fiscal year in the series	€ 39,693 Cash 2023: € 39,693 ▼ 39% vs 2022 (€ 65,145) Unfavourable step	€ 96,558 Cash 2024: € 96,558 ▲ 143% vs 2023 (€ 39,693) Favourable step	€ 217,274 Cash 2025: € 217,274 ▲ 125% vs 2024 (€ 96,558) Favourable step	▲ 125%
Retained profit	€ 93,586 Retained profit 2022: € 93,586 First fiscal year in the series	€ 180,046 Retained profit 2023: € 180,046 ▲ 92% vs 2022 (€ 93,586) Favourable step	€ 298,848 Retained profit 2024: € 298,848 ▲ 66% vs 2023 (€ 180,046) Favourable step	€ 400,993 Retained profit 2025: € 400,993 ▲ 34% vs 2024 (€ 298,848) Favourable step	▲ 34%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 90,000 Dividend 2025: € 90,000 Unchanged (€ 0) Unchanged
Bank debt	€ 13,698 Bank debt 2022: € 13,698 First fiscal year in the series	€ 9,782 Bank debt 2023: € 9,782 ▼ 29% vs 2022 (€ 13,698) Favourable step	€ 5,790 Bank debt 2024: € 5,790 ▼ 41% vs 2023 (€ 9,782) Favourable step	€ 1,719 Bank debt 2025: € 1,719 ▼ 70% vs 2024 (€ 5,790) Favourable step	▼ 70%
Balance sheet total	€ 136,972 Balance sheet total 2022: € 136,972 First fiscal year in the series	€ 220,013 Balance sheet total 2023: € 220,013 ▲ 61% vs 2022 (€ 136,972) Unchanged	€ 342,761 Balance sheet total 2024: € 342,761 ▲ 56% vs 2023 (€ 220,013) Unchanged	€ 556,104 Balance sheet total 2025: € 556,104 ▲ 62% vs 2024 (€ 342,761) Unchanged	▲ 62%

Key figures of LB Clinical Biology, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to LB Clinical Biology?

What happened at LB Clinical Biology in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 6, 2026 New annual accounts for financial year 2025: profit of € 192,145 (▲ 62% vs 2024). filed late Source: NBB ↗
Oct 12, 2021 New establishment in Namur. KBO
Oct 12, 2021 Start of the company according to the CBE. KBO

In short

From € 93,586 profit in 2022 to € 192,145 profit in 2025.

Paid € 144,435 in corporate taxes since 2022.

Best year ever: 2025, with € 192,145 profit.

Paid out € 90,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Benjamin Lardinois

LB Clinical Biology

Behind LB Clinical Biology is Benjamin Lardinois.

Directors

According to the 2025 annual accounts

Benjamin Lardinois

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rue du Sart-Mathelet 2 box A

5336 Assesse

2.323.110.309

Rue Saint-Luc(BU) 8

5004 Namur

Active since 12 October 2021

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

FITNESS CLUB MAILLEN

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0775.653.669
VAT number: BE 0775.653.669
Registered office: Rue du Sart-Mathelet 2 bus A, 5336 Assesse
Names & denominations: LB Clinical Biology
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 12 October 2021
Peppol: Active · Active since 1 Dec 2024

View on CBE Public ↗ Annual accounts (NBB) ↗